Denied PET Scan Appeals: What Reviewers Decided

Positron emission tomography, usually with CT, ordered for staging, restaging or treatment response and billed with the study code and, where applicable, the radiopharmaceutical.

What the independent reviewers decided

64%

overturned by the independent reviewer

of 151 decisions in the corpus

Source

California DMHC independent medical review determinations, 2017-2026. Public record.

Read this as a base rate, not as your odds

These are decisions about other patients, in one state, that had already been through the plan's own internal appeal and were then sent to an outside reviewer. That population is self-selected toward disputes worth pursuing, so the rate says what happened to cases like this at that stage — not what will happen to a specific claim. It is not medical or legal advice.

Why plans deny PET scan

The policy covers PET only at specified points in a treatment pathway and the request falls outside them.
The indication is treated as surveillance, which many policies exclude.
A conventional study is named as the appropriate modality for the question being asked.
The requested scan exceeds a per-episode or per-year limit.

What actually carried the cases that won

Objective findings led, but the character of the finding differs from MRI or CT: in these decisions it was usually the staging or restaging context — a documented lesion, a marker trend, a treatment point in a defined pathway. The reversals put the scan inside a pathway the reviewer could recognise. Specialty-society criteria were the authority relied on most.

What the record showed	Share of overturned decisions
Objective findings were documented	89%
The diagnosis was confirmed	45%
A published guideline supported the request	36%
The severity or urgency was documented	15%
The functional impact on the patient was documented	14%
The condition was documented as chronic or long-standing	13%
Prior treatment was documented	5%
Conservative treatment was documented as failed	2%

Shares are of the overturned decisions and do not sum to 100% — a single decision often rested on more than one, and some rested on none of these.

What the reviewers cited

Specialty-society criteria — in 47% of the overturned decisions
Clinical guidelines — in 42% of the overturned decisions
Peer-reviewed literature — in 33% of the overturned decisions
FDA labeling — in 6% of the overturned decisions
Standard of care — in 3% of the overturned decisions

PET scan denials — frequently asked

Is a denied PET scan worth appealing?

64% of 151 California independent medical reviews were overturned, the highest of the imaging group in this corpus and materially above MRI and CT.

Why does the treatment pathway matter?

Most PET policies are written as pathway rules — covered at diagnosis, at restaging, at defined response points. An appeal that establishes where in the pathway this patient sits is answering the policy on its own terms; one that argues the scan is clinically reasonable is not.

What about surveillance scans?

Surveillance exclusions are common and are among the harder bases to overturn. Where the request is genuinely a response to a documented change, the record should say so explicitly rather than leaving the scan to read as routine follow-up.

Source

California Department of Managed Health Care — independent medical review determinations

Denial reasons and criteria are described in plain language for reference and vary by plan and policy. This page reports what independent reviewers decided in a public California dataset; it is general information, not medical, legal, or coverage advice.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →